Eli Lilly and Company — LLY

Close PriceMarket CapP/E RatioForward P/E RatioImplied Growth*Implied Forward Growth*DividendP/B Ratio
$727.01$651.73B47.532.120.9%16.4%$6.00
81.0%		35.7

Revenue & Net Income

Revenue & Net Income
  Date Revenue Net Income EPS Revenue Change Net Income Change EPS Change
0 2020-12-31 $24.5B $6.2B $6.47 N/A N/A N/A
1 2021-12-31 $28.3B $5.6B $5.85 15.4% -9.9% -9.6%
2 2022-12-31 $28.5B $6.2B $6.57 0.8% 11.9% 12.3%
3 2023-12-31 $34.1B $5.2B $5.82 19.6% -16.1% -11.4%
4 2024-12-31 $45.0B $10.6B $11.76 32.0% 102.1% 102.1%
5 TTM 2025-03-31 $49.0B $11.1B $12.31 8.8% 4.9% 4.7%
6 Average 15.3% 18.6% 19.6%

EPS

EPS

Forecasts

Revenue/Net Income Forecast EPS Forecast

Y/Y % Change

Revenue YoY Change EPS YoY Change
YoY Growth Rates

LLY Year-over-Year Growth

  2020 2021 2022 2023 2024 2025 2026 Average
Revenue Growth (%) 15.4% 0.8% 19.6% 32.0% 37.2% 19.5% 20.8%
Revenue Analysts (#) 0 0 0 0 0 7 7
EPS Growth (%) -9.9% 11.9% -16.1% 102.1% 95.0% 34.4% 36.2%
EPS Analysts (#) 0 0 0 0 0 9 9

Expenses

Revenue vs Expenses Expenses % of Revenue
Year Revenue ($) Cost of Revenue ($) R&D ($) G&A ($) SG&A ($) Facilities / D&A ($) Personnel ($)
2021 $28.3B $5.8B $6.9B $6.1B $6.1B $1.5B $-289.7M
2022 $28.5B $5.1B $7.2B $6.1B $6.1B $1.5B $-372.9M
2023 $34.1B $5.6B $9.3B $6.9B $6.9B $1.5B $-461.9M
2024 $45.0B $6.7B $11.0B $8.1B $8.1B $1.8B $-461.7M
TTM $53.3B $7.4B $11.8B $9.3B $9.3B $1.9B $-443.2M
Year Revenue Change (%) Cost of Revenue Change (%) R&D Change (%) G&A Change (%) SG&A Change (%) Facilities / D&A Change (%) Personnel Change (%)
2022 0.79 -11.41 3.75 -1.21 -1.21 -1.62 28.72
2023 19.56 8.76 29.52 14.40 14.40 0.32 23.87
2024 32.00 19.74 18.01 17.16 17.16 15.67 -0.04
TTM 18.24 10.55 7.60 14.40 14.40 7.15 -4.01
No unmapped expenses.

Segment Performance

axis1_LLY_Baqsimi.png
axis1_LLY_Basaglar.png
axis1_LLY_C_O_V_I_D19_Antibodies.png
axis1_LLY_Cardiometabolic_Health.png
axis1_LLY_Collaborationand_Other_Revenue.png
axis1_LLY_Cyramza.png
axis1_LLY_Emgality.png
axis1_LLY_Erbitux.png
axis1_LLY_Humalog.png
axis1_LLY_Humulin.png
axis1_LLY_Immunology.png
axis1_LLY_Jardiance.png
axis1_LLY_Mounjaro.png
axis1_LLY_Neuroscience.png
axis1_LLY_Olumiant.png
axis1_LLY_Oncology.png
axis1_LLY_Other_Cardiometabolic_Health.png
axis1_LLY_Other_Immunology.png
axis1_LLY_Other_Neuroscience.png
axis1_LLY_Other_Oncology.png
axis1_LLY_Other_Product.png
axis1_LLY_Other_Product_Total.png
axis1_LLY_Product.png
axis1_LLY_T_Y_V_Y_T.png
axis1_LLY_Taltz.png
axis1_LLY_Trulicity.png
axis1_LLY_Verzenio.png
axis1_LLY_Zepbound.png
axis1_LLY_Zyprexa.png
SEGMENTS v2025-09-09 · 2025-09-05 15:02 UTC — Values are shown in a single scale for this table: $B. TTM values are bold. “% of Total (TTM)” shows revenue mix.
Segment 2022 Rev ($B) 2022 OI ($B) 2023 Rev ($B) 2023 OI ($B) 2024 Rev ($B) 2024 OI ($B) TTM Rev ($B) TTM OI ($B) % of Total (TTM)
Product 25.5B 0.00B 28.8B 0.00B 40.7B 0.00B 53.3B 0.00B 26.1%
Cardiometabolic Health 14.5B 0.00B 19.7B 0.00B 29.5B 0.00B 52.3B 0.00B 25.6%
Mounjaro 0.48B 0.00B 5.16B 0.00B 11.5B 0.00B 24.0B 0.00B 11.8%
Zepbound – – 0.18B 0.00B 4.93B 0.00B 17.1B 0.00B 8.4%
Oncology 5.67B 0.00B 6.66B 0.00B 8.75B 0.00B 10.0B 0.00B 4.9%
Jardiance 4.13B 0.00B 5.49B 0.00B 6.98B 0.00B 7.86B 0.00B 3.8%
Verzenio 2.48B 0.00B 3.86B 0.00B 5.31B 0.00B 6.15B 0.00B 3.0%
Immunology 3.34B 0.00B 3.80B 0.00B 4.39B 0.00B 5.59B 0.00B 2.7%
Collaborationand Other Revenue 3.08B 0.00B 5.31B 0.00B 4.29B 0.00B 4.22B 0.00B 2.1%
Trulicity 7.44B 0.00B 7.13B 0.00B 5.25B 0.00B 3.92B 0.00B 1.9%
Taltz 2.48B 0.00B 2.76B 0.00B 3.26B 0.00B 3.67B 0.00B 1.8%
Humalog 2.06B 0.00B 1.66B 0.00B 2.32B 0.00B 2.32B 0.00B 1.1%
Olumiant 1.66B 0.00B 1.85B 0.00B 1.91B 0.00B 1.91B 0.00B 0.9%
Other Oncology 1.35B 0.00B 0.83B 0.00B 1.32B 0.00B 1.77B 0.00B 0.9%
Basaglar 1.52B 0.00B 1.46B 0.00B 1.35B 0.00B 1.35B 0.00B 0.7%
Neuroscience 1.55B 0.00B 2.88B 0.00B 1.47B 0.00B 1.26B 0.00B 0.6%
T Y V Y T 0.59B 0.00B 0.79B 0.00B 1.05B 0.00B 1.05B 0.00B 0.5%
Cyramza 0.97B 0.00B 0.97B 0.00B 0.97B 0.00B 0.97B 0.00B 0.5%
Other Immunology 0.03B 0.00B 0.12B 0.00B 0.18B 0.00B 0.97B 0.00B 0.5%
Humulin 1.02B 0.00B 0.85B 0.00B 0.92B 0.00B 0.92B 0.00B 0.4%
Other Product 1.50B 0.00B 1.12B 0.00B 0.90B 0.00B 0.90B 0.00B 0.4%
Emgality 0.65B 0.00B 0.68B 0.00B 0.87B 0.00B 0.87B 0.00B 0.4%
Other Product Total 3.52B 0.00B 1.12B 0.00B 0.90B 0.00B 0.82B 0.00B 0.4%
Erbitux 0.57B 0.00B 0.60B 0.00B 0.63B 0.00B 0.63B 0.00B 0.3%
Other Neuroscience 0.56B 0.00B 0.51B 0.00B 0.49B 0.00B 0.49B 0.00B 0.2%
Zyprexa 0.34B 0.00B 1.69B 0.00B 0.12B 0.00B 0.12B 0.00B 0.1%
Baqsimi 0.14B 0.00B 0.68B 0.00B 0.03B 0.00B 0.03B 0.00B 0.0%
Other Cardiometabolic Health 0.50B 0.00B 0.53B 0.00B 0.51B 0.00B -0.39B 0.00B -0.2%
C O V I D19 Antibodies 4.04B 0.00B – – – – – – –
LLY_Reportable_axis2.png

No segment data available for LLY (axis 2).

Balance Sheet

Balance Sheet
  Metric Value
0 Total Assets $89,389M
1 Cash $3,093M
2 Total Liabilities $73,542M
3 Total Debt $38,516M
4 Total Equity $15,765M
5 Debt to Equity Ratio 2.44

EPS & Dividend

EPS & Dividend

Valuation

Valuation
Share Price Treasury Yield Estimates Fair Value (P/E) Fair Value (P/S) Current P/S Current P/E
$762.73 4.4% Nicks Growth: N/A
Nick's Expected Margin: N/A
FINVIZ Growth: 41%		 Nicks: 6
Finviz: 234		 Nick's: 0.000 14.0 62.1
Basis Year Nicks Valuation Nicks vs Share Price Finviz Valuation Finviz vs Share Price
$12.31 EPS TTM $78.70 -89.7% $2,876.67 277.2%
$21.95 EPS 2025 $140.33 -81.6% $5,129.40 572.5%
$30.91 EPS 2026 $197.61 -74.1% $7,223.22 847.0%

Implied Growth

Implied Growth
Average Median Std Dev Current Percentile
TTM Forward TTM Forward TTM Forward TTM Forward TTM Forward
Timeframe
1 Year 23.01% 16.93% 24.30% 17.22% 2.06% 0.83% 21.32% 16.78% 39.7% 39.7%
3 Years 23.01% 16.93% 24.30% 17.22% 2.06% 0.83% 21.32% 16.78% 39.7% 39.7%
5 Years 23.01% 16.93% 24.30% 17.22% 2.06% 0.83% 21.32% 16.78% 39.7% 39.7%
10 Years 23.01% 16.93% 24.30% 17.22% 2.06% 0.83% 21.32% 16.78% 39.7% 39.7%

← Back